Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs Eli Lilly And Co (LLY) Price & Performance

Bitwise Crypto Industry Innovators ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Bitwise Crypto Industry Innovators ETF vs Eli Lilly And Co — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $22.36, while Eli Lilly And Co trades at $1,214.7 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while Bitwise Crypto Industry Innovators ETF pays none. Which is the better fit depends on your goals.

BITQLLY
Sector
Crypto-linkedHealth
52-Week High
$30.43$1.24K
52-Week Low
$16.74$639.43
Market Cap
$1.10T
Enterprise Value
$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bitwise Crypto Industry Innovators ETF

BITQ trades at $22.88, up 1.42% today, but faces strong technical headwinds with 17 sell signals versus 0 buy signals across moving averages and oscillators. The stock shows bearish momentum with key resistance at $23 and support at $22. Financial metrics remain unavailable in current data, requiring verification through SEC filings.

The technical outlook appears bearish with weak momentum indicators. Investment opportunity depends on upcoming earnings clarity and institutional positioning. Primary risks include market volatility and lack of visible fundamental support until financial disclosures are updated.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bitwise Crypto Industry Innovators ETF

BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.

Read more on BITQ

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY